Multi-cancer early detection (MCED) blood tests continue to face clinical validation challenges after Grail’s Galleri test failed to meet its primary endpoint in the large NHS-Galleri trial. The three-year study, which screened over 142,000 asymptomatic participants aged 50–77, did not demonstrate a statistically significant reduction in late-stage (III–IV) cancer diagnoses compared to standard screening alone—triggering a sharp decline in the company’s share value. While secondary analyses showed a favorable trend toward fewer late-stage cancers and a meaningful reduction in stage IV diagnoses in certain cancer subgroups, the trial outcome raises fresh concerns around the real-world utility of MCED tests for…
Author: Abhay Panchal
Stool-based screening remains a cornerstone of colorectal cancer prevention, with randomized trials showing that screening can reduce CRC incidence by up to 18% and mortality by up to 33%. In the U.S., the most commonly used noninvasive stool tests include the fecal immunochemical test (FIT) and multitarget stool DNA testing (mt-sDNA), both recommended starting at age 45 for average-risk individuals. FIT detects human hemoglobin in stool and has largely replaced guaiac-based tests due to its higher sensitivity and specificity for CRC and advanced adenomas. In contrast, mt-sDNA testing (e.g., Cologuard) combines FIT with molecular biomarkers associated with colorectal neoplasia, offering…
Guardant Health has acquired MetaSight Diagnostics for $59 million upfront, with an additional $90 million tied to future regulatory and commercial milestones, as it looks to expand its multi-disease detection capabilities beyond oncology. MetaSight develops liquid biopsy diagnostics using a mass spectrometry–based multi-omics approach—including metabolomics, lipidomics, and proteomics—to identify disease biomarkers in blood samples. Its pipeline includes tests for colorectal cancer, liver fibrosis, myocardial infarction, diabetic kidney disease, and pancreatic and lung tumors. The acquisition complements Guardant’s existing blood-based colorectal cancer screening efforts and supports its broader strategy to develop diagnostics across cardiovascular, renal, neurodegenerative, and autoimmune conditions.
Stockholders of Exact Sciences have approved the company’s proposed acquisition by Abbott, with more than 99% of votes cast in favor of the transaction. Pending final regulatory approvals and other closing conditions, the deal is expected to be completed by the end of the second quarter of 2026. Upon completion, Exact Sciences shareholders will receive $105 in cash per share. The acquisition brings Abbott into Exact Sciences’ portfolio of cancer diagnostics and screening solutions, including stool-based colorectal cancer screening and multi-cancer early detection technologies currently available in the United States.
Advances in ingestible electronics are paving the way for next-generation “smart pills” that can both diagnose and treat gastrointestinal diseases from within the body. These capsule-sized devices integrate miniaturized sensors, actuators, and wireless communication systems to monitor biomarkers, assess tissue health, and transmit real-time data as they travel through the GI tract. Beyond diagnostics, emerging prototypes are being designed to deliver drugs directly to diseased tissue or collect biopsy samples using low-power mechanical systems—potentially reducing the need for invasive procedures such as endoscopy. Ongoing research is focused on overcoming key challenges related to power supply, biocompatibility, and miniaturization, with the…
In the latest edition of The Scope Forward Show, I’m joined by: Matt Schwartz, Founder & CEO of VirgoDr. Neil Parikh, Chief Innovation Officer, Connecticut GI and Chair of Innovation, GI Alliance This isn’t an interview. It’s a raw, unscripted exploration of where AI in GI is actually headed—guided by the latest headlines and hard questions. Here’s what we unpack: We also dive into: This isn’t about polyp detection anymore. It’s about: If you think AI in GI is limited to ambient listening and green bounding boxes… This conversation will challenge you. If you sense something much bigger unfolding… You shouldn’t miss this one.…
As demand grows for alternatives to costly GLP-1 therapies, AI-powered “digital twins” are emerging as a novel approach to managing chronic metabolic conditions such as diabetes and obesity. Startups like Twin Health are combining wearable sensor data with machine learning to create individualized metabolic models that guide real-time lifestyle interventions. By continuously analyzing biomarkers and behavioral inputs, these virtual replicas aim to support sustained weight loss and glycemic control without pharmacologic therapy. Early patient experiences suggest that personalized, data-driven recommendations may help overcome the limitations of traditional diet-based approaches, offering a scalable, non-drug pathway for long-term chronic disease management.
The U.S. healthcare system is approaching a tipping point, driven by three converging threats: rising care costs, a growing chronic disease burden, and a physician workforce trained for a rapidly outdated model of care. With national healthcare spending projected to surpass $7 trillion by the end of the decade, incremental policy fixes are unlikely to keep pace with mounting financial and clinical pressures. As chronic conditions like diabetes continue to drive long-term complications and high-cost care, prevention alone may not be sufficient to offset system-wide strain. In response, generative AI is emerging as a potential force multiplier—automating routine monitoring and…
New research presented at the 2026 Crohn’s & Colitis Congress® highlights a rapidly evolving therapeutic landscape in inflammatory bowel disease (IBD), spanning metabolic drugs, engineered microbiome therapies, and real-world treatment data. GLP-1 receptor agonists—commonly used for obesity and diabetes—were associated with improved IBD outcomes across independent cohorts, including reduced corticosteroid use, fewer hospitalizations, intestinal surgeries, and lower mortality, without increased surgical risk. These findings suggest potential benefits beyond metabolic disease and warrant further prospective evaluation in IBD populations. Researchers also introduced a next-generation live biotherapeutic for ulcerative colitis: a genetically engineered strain of E. coli Nissle 1917 designed to selectively…
Independent physician practices are facing mounting financial strain as operating costs rise faster than reimbursements, driving many toward consolidation with hospitals, insurers, or private equity firms. Lingering pandemic-related revenue drops, combined with increasing expenses tied to staffing, compliance, technology, and malpractice coverage, are further tightening cash flow across midsize practices. These pressures are reshaping how practices approach growth and financing. Traditional lenders are placing greater emphasis on predictable cash flow, EBITDA margins, accounts receivable timelines, and payer mix—factors that can significantly influence access to capital. In this environment, practices with inconsistent revenue cycles or heavy dependence on government payers may…